AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments.
ByAinvest
Monday, Aug 11, 2025 10:20 am ET1min read
MaxCyte has signed a strategic platform license with Adicet Bio to use its Flow Electroporation technology and ExPERT platform for research, clinical, and commercial purposes. Adicet will use MaxCyte's technology to develop allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. The agreement grants Adicet non-exclusive rights to use MaxCyte's ExPERT technology for large-scale production of off-the-shelf cell therapies.
Title: MaxCyte Partners with Adicet Bio to Advance Gamma Delta T Cell TherapiesMaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company, has signed a strategic platform license agreement with Adicet Bio, Inc. to support the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. The agreement grants Adicet Bio non-exclusive rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes [1].
Under the terms of the agreement, Adicet Bio will utilize MaxCyte's technology to enhance its proprietary manufacturing process, which combines non-viral gene editing with a robust expansion platform to deliver potent cell therapy products. The collaboration aims to enable scalable production of off-the-shelf, allogeneic cell therapies for various clinical applications [1].
MaxCyte's Flow Electroporation® technology and ExPERT™ platform are designed to support complex and scalable cell engineering, delivering high transfection efficiency and cell viability [2]. Maher Masoud, President and Chief Executive Officer of MaxCyte, stated, "We are pleased to support Adicet Bio as they expand their allogeneic gamma delta T cell manufacturing capabilities to include non-viral gene editing delivery. This collaboration underscores the versatility of our platform and its ability to enable the development of next-generation cell therapy candidates with increased efficiency and accessibility" [1].
MaxCyte will receive platform licensing fees and program-related revenue as part of the agreement. However, the exact terms and conditions of the agreement, including the potential revenue streams, were not disclosed [1].
The strategic platform license agreement between MaxCyte and Adicet Bio is a significant step in advancing the development of next-generation cell therapies. It highlights the potential of MaxCyte's platform technology in enabling the efficient and scalable production of cell-based therapeutics [1].
References:
[1] https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-signs-platform-license-agreement-adicet-bio
[2] https://www.morningstar.com/news/globe-newswire/9504081/maxcyte-signs-platform-license-agreement-with-adicet-bio
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet